• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于细胞外囊泡的严重急性呼吸综合征冠状病毒2疫苗

Extracellular Vesicle-Based SARS-CoV-2 Vaccine.

作者信息

Matsuzaka Yasunari, Yashiro Ryu

机构信息

Division of Molecular and Medical Genetics, The Institute of Medical Science, Center for Gene and Cell Therapy, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.

Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.

出版信息

Vaccines (Basel). 2023 Feb 24;11(3):539. doi: 10.3390/vaccines11030539.

DOI:10.3390/vaccines11030539
PMID:36992123
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10058598/
Abstract

Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines.

摘要

信使核糖核酸(RNA)疫苗主要用作严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗。尽管存在一些关于储存、稳定性、有效期和副作用的问题,但病毒载体疫苗仍被广泛用于预防和治疗各种疾病。最近,由于其安全性和能够逃避中和抗体,病毒载体封装的细胞外囊泡(EVs)被认为是有用的工具。在此,我们总结了基于EV的SARS-CoV-2疫苗潜在的细胞机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f15/10058598/8aad12407b0c/vaccines-11-00539-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f15/10058598/3edb4bd7e844/vaccines-11-00539-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f15/10058598/8aad12407b0c/vaccines-11-00539-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f15/10058598/3edb4bd7e844/vaccines-11-00539-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f15/10058598/8aad12407b0c/vaccines-11-00539-g002.jpg

相似文献

1
Extracellular Vesicle-Based SARS-CoV-2 Vaccine.基于细胞外囊泡的严重急性呼吸综合征冠状病毒2疫苗
Vaccines (Basel). 2023 Feb 24;11(3):539. doi: 10.3390/vaccines11030539.
2
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.一种基于细菌细胞外囊泡的鼻腔内疫苗可预防 SARS-CoV-2 感染,诱导针对野生型和 Delta 变异株的中和抗体。
J Extracell Vesicles. 2022 Mar;11(3):e12192. doi: 10.1002/jev2.12192.
3
Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.基于细胞外囊泡的、有望用于对抗包括SARS-CoV-2在内的病毒的疫苗。
Biology (Basel). 2021 Jan 27;10(2):94. doi: 10.3390/biology10020094.
4
Edible Plant-Derived Extracellular Vesicles for Oral mRNA Vaccine Delivery.用于口服mRNA疫苗递送的可食用植物源细胞外囊泡
Vaccines (Basel). 2024 Feb 15;12(2):200. doi: 10.3390/vaccines12020200.
5
Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection.用病毒刺突蛋白的 RBD 对细胞外囊泡进行标记,以递呈抗病毒药物来对抗 SARS-CoV-2 感染。
J Control Release. 2021 Jul 10;335:584-595. doi: 10.1016/j.jconrel.2021.05.049. Epub 2021 Jun 3.
6
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.表达严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的新城疫病毒(NDV)作为候选疫苗。
bioRxiv. 2020 Jul 28:2020.07.26.221861. doi: 10.1101/2020.07.26.221861.
7
Investigation of Extracellular Vesicles From SARS-CoV-2 Infected Specimens: A Safety Perspective.从安全角度对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染样本中的细胞外囊泡进行研究
Front Immunol. 2021 Apr 22;12:617042. doi: 10.3389/fimmu.2021.617042. eCollection 2021.
8
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.两亲性纳米颗粒疫苗展示糖基化 Spike S1 结构域,诱导针对 SARS-CoV-2 变体的中和抗体反应。
mBio. 2021 Oct 26;12(5):e0181321. doi: 10.1128/mBio.01813-21. Epub 2021 Oct 12.
9
Protective role of engineered extracellular vesicles loaded quercetin nanoparticles as anti-viral therapy against SARS-CoV-2 infection: A prospective review.载有槲皮素纳米粒的工程细胞外囊泡作为抗 SARS-CoV-2 感染的抗病毒治疗的保护作用:前瞻性综述。
Front Immunol. 2022 Dec 8;13:1040027. doi: 10.3389/fimmu.2022.1040027. eCollection 2022.
10
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.一种基于细菌细胞外囊泡的抗SARS-CoV-2鼻内疫苗可预防疾病,并引发针对野生型和Delta变体的中和抗体。
bioRxiv. 2022 Feb 1:2021.06.28.450181. doi: 10.1101/2021.06.28.450181.

引用本文的文献

1
Exosomes and SARS-CoV-2 infection.外泌体与严重急性呼吸综合征冠状病毒2感染
Front Immunol. 2024 Nov 26;15:1467109. doi: 10.3389/fimmu.2024.1467109. eCollection 2024.
2
Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of a extracellular vesicle-based vaccine prototype in murine systemic candidiasis.Toll 样受体 4(TLR4)是触发基于细胞外囊泡的疫苗原型在小鼠系统性念珠菌病中发挥保护作用的主要模式识别受体。
mSphere. 2024 Aug 28;9(8):e0046724. doi: 10.1128/msphere.00467-24. Epub 2024 Jul 22.
3
Exosome-Mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control and Vaccine Design.

本文引用的文献

1
COVID19 biomarkers: What did we learn from systematic reviews?COVID19 生物标志物:系统评价给我们带来了哪些启示?
Front Cell Infect Microbiol. 2022 Dec 13;12:1038908. doi: 10.3389/fcimb.2022.1038908. eCollection 2022.
2
Guidelines for Triage of COVID-19 Patients Presenting With Multisystemic Symptoms.COVID-19 患者出现多系统症状的分诊指南。
Qual Manag Health Care. 2023;32(Suppl 1):S3-S10. doi: 10.1097/QMH.0000000000000398.
3
Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase.
外泌体介导的抗原递送:揭示病毒感染控制和疫苗设计中的新策略。
Vaccines (Basel). 2024 Mar 7;12(3):280. doi: 10.3390/vaccines12030280.
口服 GS-441524 衍生物:新一代 SARS-CoV-2 依赖 RNA 的 RNA 聚合酶抑制剂。
Front Immunol. 2022 Dec 6;13:1015355. doi: 10.3389/fimmu.2022.1015355. eCollection 2022.
4
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments.严重急性呼吸综合征冠状病毒2(SARS-CoV-2):一篇强调其进化与治疗方法的最新综述
Vaccines (Basel). 2022 Dec 14;10(12):2145. doi: 10.3390/vaccines10122145.
5
Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants.同源或异源灭活(科兴新冠疫苗/BBIBP-CorV)和重组蛋白亚单位疫苗(ZF2001)诱导产生的抗体显著增强了对B.1.351、B.1.617.2和B.1.1.529变体的抑制能力。
Vaccines (Basel). 2022 Dec 9;10(12):2110. doi: 10.3390/vaccines10122110.
6
Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?针对 SARS-CoV-2 感染的病毒复制和炎症途径的早期药物治疗策略:酮咯酸赖氨酸盐有何潜在作用?
Molecules. 2022 Dec 15;27(24):8919. doi: 10.3390/molecules27248919.
7
Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments.用于新型临床治疗的细胞外囊泡的纯化、修饰及应用进展
Membranes (Basel). 2022 Dec 8;12(12):1244. doi: 10.3390/membranes12121244.
8
New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.新型细胞外囊泡治疗策略:递送 CRISPR 用于癌症治疗。
Int J Mol Sci. 2022 Dec 12;23(24):15758. doi: 10.3390/ijms232415758.
9
Taxonomic Changes for Human Viruses, 2020 to 2022.2020 年至 2022 年人类病毒分类学变化。
J Clin Microbiol. 2023 Jan 26;61(1):e0033722. doi: 10.1128/jcm.00337-22. Epub 2022 Dec 21.
10
Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication.mTOR 抑制剂在控制 SARS-CoV-2 病毒复制中的治疗作用。
Mol Biol Rep. 2023 Mar;50(3):2701-2711. doi: 10.1007/s11033-022-08188-1. Epub 2022 Dec 20.